Dear {{Account.Name}}
I hope you won’t mind me keeping in touch with you during this difficult period. This is a challenging time for all of us - for you, your patients, and your staff. I respect that now is not an appropriate time to discuss the treatment of myelofibrosis (MF), so am sharing some interesting information about MF with you.
|
|
|
|
Myelofibrosis (MF) by the numbers |
|
|
|
MF is a progressive disease that worsens without treatment1,2
|
|
|
|
Approximately 50% of high-risk patients with MF will survive for ≤2.3 years3
|
|
|
|
|
Approximately 50% of patients with MF have a median overall survival of ≤4 years, including intermediate-2 patients3
|
|
|
|
|
Approximately 50% of patients with MF die due to disease progression or related complications3,4
|
|
|
|
|
Even for intermediate-2 patients, median overall survival is 4 years3
|
|
|
|
JAKAVI is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis5
|
|
|
|
Should you require more information, please do not hesitate to contact me.
Best regards,
{{userName}},
{{userEmailAddress}}
|
|
|
|
References: 1. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363(12):1117-1127. 2. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 2014; 7:89-101. 3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113(13):2895-2901. 4. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Pro 2012; 87(1):25-33. 5. JAKAVI® Package Insert (April 2017).
|
|
|
|
 JAKAVI 5 mg, 15 mg & 20 mg tablets. Reg. No.: 48/34/0109/110/111. Composition: Each JAKAVI 5 mg, 15 mg and 20 mg tablet contains 5 mg, 15 mg and 20 mg ruxolitinib respectively. Before prescribing, consult full Professional Information, approved 20 April 2017.
|
|
|
|
Novartis Adverse Drug Reaction Reporting: Email: patient safety.sacg@novartis.com.
Web: https://psi.novartis.com/. Tel: 0861 929-929. Fax: 011 929-2262.
Novartis South Africa (Pty) Ltd., Magwa Crescent West, Waterfall City, Jukskei View, 2090, SOUTH AFRICA.
Tel. (+27) 11 347-6600. Co. Reg. No. 1946/020671/07.
ZA2005114296. Expiry date: 22 April 2022.
|
|
|
|
You are receiving this email because you have been identified as a valuable Novartis customer and we respect your privacy. For more information on how we treat your personal information, please see our privacy notice (link NVS privacy notice). To manage your subscription or to unsubscribe from further Novartis communication please click here.
|
|
|
|
|
